Skip to main content
HR 2139 117th Congress House Health Congressional oversight Government information and archives Government studies and investigations Health care costs and insurance Inflation and prices Medicaid Medicare Prescription drugs Public contracts and procurement Retail and wholesale trades

Medicare Drug Price Negotiation Act

Introduced: June 23, 2021 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 24, 2021
Referred to the Subcommittee on Health.
Mar 23, 2021
Referred to the Subcommittee on Health.
Mar 23, 2021
Introduced in House
Mar 23, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Medicare Drug Price Negotiation Act

This bill makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs).

Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations.

If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the median price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost.

Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

What's happening now March 24, 2021

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2139: Medicare Drug Price Negotiation Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-2139/
MLA
"H.R. 2139: Medicare Drug Price Negotiation Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-2139/.
Bluebook (legal)
H.R. 2139, 117th Cong. (2026), https://openamerica.io/bill/117-HR-2139/.
Markdown link
[H.R. 2139: Medicare Drug Price Negotiation Act](https://openamerica.io/bill/117-HR-2139/)
Report a problem